Epidermal growth factor receptor-targeted therapy for pancreatic cancer

Seminars in Oncology

Volumn 29, Issue 5 SUPPL. 14, 2002, Pages 31-37

  Xiong, Henry Q ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CETUXIMAB; ELB 569; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKING AGENT; ERLOTINIB; GEFITINIB; GEMCITABINE; MURINE MONOCLONAL ANTIBODY M225; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CARCINOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RASH; SIGNAL TRANSDUCTION;

EID: 0037010091     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70088-2     Document Type: Conference Paper

References (62)

1. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990
2. Prenzel N, Fischer OM, Streit S, et al: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31, 2001
3. Sonenshein GE: Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol 8:113-119, 1997
4. Alessi DR, Cohen P: Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8:55-62, 1998
5. Birge RB, Knudsen BS, Besser D, et al: SH2 and SH3-containing adaptor proteins: Redundant or independent mediators of intracellular signal transduction. Genes Cells 1:595-613, 1996
6. Bromberg J, Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19:2468-2473, 2000
7. Gschwind A, Zwick E, Prenzel N, et al: Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20:1594-1600, 2001
8. Earp HS, Dawson TL, Li X, et al: Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35:115-132, 1995
9. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
10. Voldborg BR, Damstrup L, Spang-Thomsen M, et al: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197-1206, 1997
11. Xu YH, Richert N, Ito S, et al: Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A 81:7308-7312, 1984
12. Velu TJ, Beguinot L, Vass WC, et al: Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238:1408-1410, 1987
13. Quon H, Liu FF, Cummings BJ, et al: Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 23:147-159, 2001
14. Skirnisdottir I, Sorbe B, Seidal T, et al: The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11:119-129, 2001
15. Pawlowski V, Revillion F, Hebbar M, et al: Prognostic value of the type 1 growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:4217-4225, 2000
16. Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460, 1993
17. Yamanaka Y, Friess H, Kobrin MS, et al: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565-569, 1993
18. Landis SH, Murray T, Bolden S, et al: Cancer statistics 1999. CA Cancer J Clin 49:8-31, 1999
19. Hawes RH, Xiong Q, Waxman I, et al: A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 95:17-31, 2000
20. Burris III HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
21. Hruban RH, Goggins M, Parsons J, et al: Progression model for pancreatic cancer. Clin Cancer Res 6:2969-2972, 2000
22. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al: K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allelespecific oligonucleotide hybridization. Am J Pathol 143:545-554, 1993
23. Casey G, Yamanaka Y, Friess H, et al: p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 69:151-160, 1993
24. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60:2002-2006, 2000
25. Hu YX, Watanabe H, Ohtsubo K, et al: Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 3:1473-1477, 1997
26. Miller DW, Fontain M, Kolar C, et al: The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 107:301-306, 1996
27. Arlt A, Vorndamm J, Breitenbroich M, et al: Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxonibicin. Oncogene 20:859-868, 2002
28. Lemoine NR, Hughes CM, Barton CM, et al: The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166:7-12, 1992
29. Funatomi H, Itakura J, Ishiwata T, et al: Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 72:512-517, 1997
30. Perrotte P, Matsumoto T, Inoue K, et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-265, 1999
31. Shi Q, Abbruzzese JL, Huang S, et al: Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5:3711-3721, 1999
32. Kornmann M, Beget HG, Korc M, et al: Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 17:169-175, 1998
33. Schreiber AB, Winkler ME, Derynck R, et al: Transforming growth factor-alpha: A more potent angiogenic mediator than epidermal growth factor. Science 232:1250-1253, 1986
34. Goldman CK, Kim J, Wong WL, et al: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133, 1993
35. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
36. Bruns CJ, Solorzano CC, Harbison MT, et al: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935, 2000
37. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
38. Torrance CJ, Jackson PE, Montgomery E, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024-1028, 2000
39. Sato JD, Kawamoto T, Le AD, et al: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511-529, 1983
40. Kawamoto T, Sato JD, Le A, et al: Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an antireceptor monoclonal antibody. Proc Natl Acad Sci U S A 80:1337-1341, 1983
41. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
42. Ennis BW, Valverius EM, Bates SE, et al: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3:1830-1838, 1989
43. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
44. Baselga J, Norton L, Masui H, et al: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993
45. Divgi CR, Welt S, Kris M, et al: Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97-104, 1991
46. Khazaeli MB, LoBuglio AF, Falcey JW, et al: Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. Proc Am Soc Clin Oncol 19:207a, 2000 (abstr 808)
47. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318, 1995
48. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
49. Prewett M, Rothman M, Waksal H, et al: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4:2957-2966, 1998
50. Bianco C, Bianco R, Tortora G, et al: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type protein kinase A antisense oligonucleotide. Clin Cancer Res 6:4343-4350, 2000
51. Ciardiello F, Bianco R, Damiano V, et al: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6:3739-3747, 2000
52. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174, 2000
53. Overholser JP, Prewett MC, Hooper AT, et al: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74-82, 2000
54. Yang X, Jia X, Corvalan JR, et al: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17-23, 2001
55. Yang XD, Jia XC, Corvalan JR, et al: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59:1236-1243, 1999
56. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
57. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001
58. Kunkel MW, Hook KE, Howard CT, et al: Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs 13:295-302, 1996
59. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 2000
60. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
61. Figlin RA, Belldegrun A, Lohner ME, et al: ABX-EGF: a fully human anti-EGF receptor antibody in patients with advanced cancer. Proc Am Soc Clin Oncol 20:276a, 2001 (abstr 1102)
62. Abbruzzese J, Rosenberg A, Xiong Q, et al: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 20:130a, 2001 (abstr 518)